Tirzepatide produced dose-dependent weight loss of 8–12% in a meta-analysis of 7 trials with 4,795 participants, including the latest SURMOUNT-2 data.
-11.8% body weight at 15 mgThe highest tirzepatide dose produced nearly 12% body weight loss versus placebo in pooled trial data
What the researchers found
Weight loss was dose-dependent and significant at all three dose levels compared to placebo:
- 5 mg: -8.07% body weight (about 7.5 kg lost)
- 10 mg: -10.79% body weight (about 11 kg lost)
- 15 mg: -11.83% body weight (about 11.5 kg lost)
All three doses also reduced BMI and waist circumference. The proportion of patients achieving meaningful weight loss thresholds (5%, 10%, 15%, 20%, and 25%) was significantly higher with tirzepatide at all dose levels. Beyond weight, tirzepatide reduced blood pressure, blood sugar, and lipid levels.
Why it matters
This meta-analysis includes the SURMOUNT-2 trial data, making it one of the most comprehensive summaries of tirzepatide's weight loss efficacy. The dose-dependent pattern helps clinicians understand the expected range of weight loss at each dose level. The consistent metabolic improvements (blood pressure, lipids, blood sugar) suggest benefits beyond just weight reduction.
The numbers in context
- 7 RCTs, 4,795 participants
- 5 mg: -8.07% BW (MD; 95% CI -11.01 to -5.13), -7.5 kg
- 10 mg: -10.79% BW (MD; 95% CI -13.86 to -7.71), -11.0 kg
- 15 mg: -11.83% BW (MD; 95% CI -14.52 to -9.14), -11.5 kg
- All doses reduced BMI, waist circumference, blood pressure, glucose, and lipids
- GI side effects most common but mild-to-moderate and transient
How the study worked
Systematic search of PubMed, Embase, Cochrane, Web of Science, and ClinicalTrials.gov through April 2024. Included 7 randomized controlled trials comparing once-weekly subcutaneous tirzepatide versus placebo in adults with or without type 2 diabetes. Trials ranged from 12 to 72 weeks. Risk of bias assessed using Cochrane RoB-2 tool. Statistical analysis performed with RevMan 5.4.1.
Who was studied
4,795 adults with or without type 2 diabetes across 7 randomized controlled trials of tirzepatide vs placebo
What this study cannot tell us
Trial durations ranged from 12 to 72 weeks, and pooling across different durations could dilute the long-term effect. The meta-analysis groups trials in patients with and without diabetes, which may differ in weight loss response. Placebo-subtracted differences depend on placebo arm weight changes, which varied across trials. Long-term weight maintenance data beyond 72 weeks is not included.
How to read the evidence
Rated strong: meta-analysis of 7 randomized controlled trials with clear dose-response relationship and large total sample size.
When this study was published
Published in 2024, including SURMOUNT-2 data. Represents the most current comprehensive weight loss analysis for tirzepatide.
The bigger picture
This is one of the most comprehensive meta-analyses of tirzepatide for weight loss, incorporating the SURMOUNT-2 trial data. The dose-response pattern helps clinicians understand the tradeoffs between higher weight loss and increased side effects at each dose level.
Questions still open
- Is the additional 1% weight loss from 10 mg to 15 mg worth the increased side effects?
- How does long-term weight maintenance compare across doses?
Common questions
How much weight will I lose on tirzepatide?
Are tirzepatide side effects worse at higher doses?
Read the original research
Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.
Endocrine, 86(1), 70-84
Citation
Qin, Wenhui; Yang, Jun; Ni, Ying; Deng, Chao; Ruan, Qinjuan; Ruan, Jun; Zhou, Peng; Duan, Kai. (2024). Efficacy and safety of once-weekly tirzepatide for weight management compared to placebo: An updated systematic review and meta-analysis including the latest SURMOUNT-2 trial.. Endocrine, 86(1), 70-84. https://doi.org/10.1007/s12020-024-03896-z